Condition: Locally Advanced or Metastatic Breast Cancers · Sponsor: Institut Claudius Regaud
This is a multicenter, prospective, non-randomized, open-label, pharmacokinetic study, aiming to compare the plasma exposure of the payload (free-DXd) in patients treated by T-DXd for locally advanced or metastatic breast cancer according to their BMI. The primary objective is to compare plasma exposition of the payload (free-DXd) between overweight or obese (BMI\>25) and normal weight (BMI≤25) breast cancer patients during the first 3 cycles of Trastuzumab-Deruxtecan (T-DXd). A total of 210 patients will have to be enrolled in this study with the following repartition: N = 105 patients with a BMI ≤ 25 (normal weight patients). N = 105 patients with a BMI \> 25 (overweight or obese patients) with at least 30 obese patients (BMI\>30).
This description comes directly from the study's public registry record.
Florence DALENC, MD, Prof · +33531155104 · dalenc.florence@iuct-oncopole.fr
Always discuss trial participation with your own doctor first.
| Institut de Cancérologie de l'Ouest - Site Angers | Angers, France | Not Yet Recruiting |
| Centre Georges François Leclerc | Dijon, France | Not Yet Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Not Yet Recruiting |
| CHU de Nîmes | Nîmes, France | Recruiting |
| Institut Curie - Site Paris | Paris, France | Not Yet Recruiting |
| Centre Eugène Marquis | Rennes, France | Recruiting |
| Institut de Cancérologie de l'Ouest - Site Saint Herblain | Saint-Herblain, France | Not Yet Recruiting |
| Centre Paul Strauss | Strasbourg, France | Recruiting |
| IUCT-O | Toulouse, France | Recruiting |
| Institut de Cancérologie de Lorraine | Vandœuvre-lès-Nancy, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07195344